A promising therapeutic approach of dendritic cell vaccines for ovarian cancer

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, primarily due to its often late-stage diagnosis and the development of resistance to conventional therapies. In recent years, significant advancements in immunotherapy have highlighted the potential of dendritic cell (DC) vaccines as a novel therapeutic approach. This review aims to thoroughly evaluate the current landscape and the future potential of DC vaccinations for OC therapy. Recent Studies have provided evidence that DC vaccines can generate specific T-cell responses, thereby enhancing the immunogenicity of ovarian tumors. Furthermore, combining DC vaccines with other therapeutic modalities, such as checkpoint inhibitors and chemotherapy, has shown considerable promise in overcoming the immune evasion mechanisms employed by tumors. However, several challenges remain, including optimizing antigen selection, improving DC maturation and migration, and countering tumor-induced immunosuppression. Continued research is essential for fully unlocking the potential of DC vaccines in improving outcomes for ovarian cancer patients.Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, primarily due to its often late-stage diagnosis and the development of resistance to conventional therapies. In recent years, significant advancements in immunotherapy have highlighted the potential of dendritic cell (DC) vaccines as a novel therapeutic approach. This review aims to thoroughly evaluate the current landscape and the future potential of DC vaccinations for OC therapy. Recent Studies have provided evidence that DC vaccines can generate specific T-cell responses, thereby enhancing the immunogenicity of ovarian tumors. Furthermore, combining DC vaccines with other therapeutic modalities, such as checkpoint inhibitors and chemotherapy, has shown considerable promise in overcoming the immune evasion mechanisms employed by tumors. However, several challenges remain, including optimizing antigen selection, improving DC maturation and migration, and countering tumor-induced immunosuppression. Continued research is essential for fully unlocking the potential of DC vaccines in improving outcomes for ovarian cancer patients.

Keywords:

Ovarian Carcinoma , DC subsets , Immunotherapy , Dendritic Cell Vaccine , Hereditary Ovarian Cancer